PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Quinestrol”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1975

The effects of stilboestrol and quinestrol upon coagulation and fibrinolysis during the puerperium.

Two oestrogens, stilboestrol and quinestrol, were used to inhibit lactation and their effects upon coagulation and fibrinolysis were compared with control patients before delivery, during the puerperium and six weeks after delivery. During the first week of the puerperium, stilboestrol therapy was associated with rises of factors IX and X and quinestrol therapy with rises of factors IX and II. Six weeks after delivery, the clotting factors were similar to the control values in those who had received stilboestrol but factor II was still raised in the quinestrol treated patients. Additionally, a significant rise of factor X in the quinestrol group was noted at this time. Plasma antithrombin levels rose during the first week of the puerperium in all three groups but, six weeks after delivery, they were lower in those who had received oestrogens. Stilboestrol and quinestrol were also associated with a rise of plasminogen and antiplasmin concentration during the first week of the puerperium. Six weeks after delivery, quinestrol treated patients still had raised levels of plasminogen and antiplasmin while the stilboestrol treated patients only had raised levels of antiplasmin. These changes in coagulation and fibrinolysis are similar to those reported during oral contraceptive therapy. The persisting changes six weeks after delivery in women who had taken quinestrol might indicate an increased thrombogenic risk when long acting oestrogen preparations are used to inhibit lactation.

Antithrombins↗
PubMed1978

Replacement estrogen therapy for menopausal vasomotor flushes. Comparison of quinestrol and conjugated estrogens.

Quinestrol, conjugated estrogens, or placebo was used to treat 156 patients with pernicious vasomotor instability in a prospective, double-blind, randomized, multiinvestigator trial. Vasomotor flushes were severe in approximately 80% of the cases and moderate in 20%, relatively equally distributed among the various drug groups. Both qinestrol and conjugated estrogens were significantly more effective than placebo in relieving vasomotor symptoms (by chi2 analysis, P less than or equal to 0.05). Greatest improvement was seen in the group receiving the higher once weekly quinestrol dosage of 0.2 mg followed by the group on the lower quinestrol dosage of 0.1 mg once weekly and the group on conjugated estrogens, 1.25 mg daily for 21 days on and 7 days off. No significant difference in relief of vasomotor flushes was shown between the active drug groups. No drug-related complications or side reactions of significance occurred. The results indicate that once weekly quinestrol is effective in relieving the vasomotor symptoms of the menopause. Either of two once weekly quinestrol regimens is an effective as conjugated estrogens given daily in a cyclic manner and therefore offers an alternative form of exogenous estrogen therapy.

Chemical Phenomena↗
PubMed1978

Effects of quinestrol on hepatic function in the rat.

Hepatic function in female rats given 200 microgram of quinestrol every 15 days for up to 210 days was studied. Prolonged treatment with quinestrol affected liver weight, serum cholestrol levels, biliar flux, and bromosulphthalein test, but these parameters tended toward control levels after 30 days of treatment. Quinestrol failed to affect alkaline phosphatase, oxalacetic and pyruvic transaminases and the concentration of bilirubin in serum and bile. The effects of quinestrol on hepatic function are similar to the effects of other estrogen derivatives.

Alkaline Phosphatase↗
PubMed1978

The effects of quinestrol and bromocriptine on blood coagulation, serum prolactin and serum FSH levels in puerperal women.

The effects of bromocriptine and quinestrol upon coagulation and fibrinolysis during the puerperium were studied. Quinestrol therapy was associated with increased levels of factors VII and IX and decreased antithrombin activity on the sixth postpartum day, and increased factor IX and plasminogen levels on the fourteenth postpartum day. Six weeks after delivery elevated levels of factors II and VII and of plasminogen were recorded in women given quinestrol. Bromocriptine therapy only caused an increase in the level of factor IX at six weeks after delivery. Compared to controls, patients given bromocriptine had lower prolactin and higher FSH levels during the puerperium whereas the patients given quinestrol had increased prolactin levels and a late fall in FSH levels.

Blood Coagulation↗
PubMed1977

[Changes in carbohydrate tolerance in the puerperium by inhibition of lactation with bromocriptine and quinestrol (author's transl)].

In the present study the influence of bromocriptine on carbohydrate tolerance was examined and its effects compared with those of an estrogenic compound (Quinestrol). Sixteen patients were studied in each group. The controls consisted of 16 women who breastfed their children. No significant difference was found in the oGTT in patients who had Quinestrol compared with the controls. However blood sugar values in women receiving bromocriptine were significantly lowered when compared with values of individuals who had Quinestrol. The reduction of blood sugar values depends on the dosage of bromocriptine. Inhibition of lactation with bromocriptine may lead to false negative results in patients who are at risk to have a prediabetic condition.

Blood Glucose↗
PubMed1979

The treatment of postmenopausal syndrome by monthly oral doses of quinestrol.

Seventy patients between the ages of 37 and 59 suffering from the menopausal syndrome were included in a clinical trial and treated for a period of 6 to 18 months. Out of the seventy, 43 were suffering from spontaneous and 27 from surgical menopause. Forty of them were given 1 mg of quinestrol and 30 received placebo. The drug was administered orally in a one-tablet dose once a month. An improvement took place in 35 (87.5%) of the women receiving quinestrol but in only 15 (50%) of those receiving placebo. Among the patients with spontaneous menopause an improvement was seen in 22 out of 25 (88%) receiving quinestrol, compared with 9 out of 18 (50%) receiving placebo. Tolerance of the drug was good and most of the laboratory tests as well as blood pressure and body weight showed statistically non-significant changes. This kind of treatment is expecially suitable when daily intake is undesirable.

Administration, Oral↗
PubMed1975

Further evaluation of quinestrol in the inhibition of lactation: a double-blind comparison of two dose levels against placebo.

One hundred and ninetysix post-partum women, in whom lactation was to be prevented, were given under double-blind conditions either placebo or quinestrol 2 mg or 4 mg as a single oral dose within twentyfour hours of delivery. Early assessment of the results gave a failure rate of 58 per cent, 15 per cent and 5 per cent respectively, with statistically significant differences among the three groups of patients. At the follow-up evaluation, which could be made in only about one third of the women, breast troubles were recorded in 20 to 30 per cent, without significant differences among the groups. Post-partum amenorrhea showed a progressive prolongation from an average of 47.9 days in the controls to 64.6 and 72.6 days respectively in the 2 and 4 mg quinestrol groups. Adverse reactions, represented by delayed uterine involution during hospital stay and abnormal uterine bleeding in the late puerperium, were somewhat more frequent in the higher dose group than in the lower dose and control groups. On the basis of the prsent findings and of similar, though rare, experiences reported in the relevant literature, the question is therefore raised whether the 2 mg quinestrol dose would not be preferable to the 4 mg one for routine use in post-partum nonusing women.

Clinical Trials as Topic↗
PubMed1978

Comparison of quinestrol and Tace for relief of postpartum breast discomfort.

A single 2-mg dose of quinestrol was demonstrated safe and effective for controlling postpartum lactation and for alleviating breast discomfort. A double-blind comparison to Tace 72 mg every 12 hours for 2 days, and to placebo, was made in 134 patients. The single oral dose of quinestrol showed efficacy equal to the 2-day regimen of Tace. Both were superior to placebo.

Adolescent↗
PubMed1980

High-pressure liquid chromatographic assay of quinestrol tablets.

A specific assay for quinestrol was developed using high-pressure liquid chromatography. The estrogen was separated from tablet excipients on a chemically bonded hydrocarbon column utilizing acetonitrile-water as the mobile phase. Linearity studies were carried out using peak height measurements, and the detector response to the concentration of the steroid was confirmed. This procedure was rapid, accurate precise, and specific for the assay of the synthetic estrogen in the presence of formulation excipients and structurally similar estrogens.

Chromatography, High Pressure Liquid↗
PubMed1975

Effect of quinestrol on plasma and urinary gonadotropins of postmenopausal women.

Ten postmenopausal women were given a 4-mg load of quinestrol by mouth and plasma FSH and LH were serially determined at monthly intervals. By bioassay, total urinary gonadotropins were also measured at the same times. Plasma FSH and apparent total gonadotropin levels in the urine were depressed to very low levels up to 3 months, while plasma LH was slightly affected. Tentative explanations of this discrepancy are presented.

Administration, Oral↗
PubMed1977

Effect of quinestrol on plasma lipids in women.

The effect of Quinestrol (3-0-cyclopentyl-17alpha-ethinyl-1, 3, 5 (10)-triene-3,17-diol), a long acting estrogenic contraceptive steroid, on plasma lipids has been studied in ten women for three months. It was found to lower plasma free fatty acids, cholesterol and cholesterol esters, but to increase plasma phospholipids and triglycerides. The possible causes of these alterations are discussed.

Adolescent↗